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© 2016 by the AGA InstituteBACKGROUND & AIMS: Crohn’s disease (CD) is a highly her-
itable disease that is particularly common in the Ashkenazi
Jewish population. We studied 2 large Ashkenazi Jewish fam-
ilies with a high prevalence of CD in an attempt to identify
novel genetic risk variants. METHODS: Ashkenazi Jewish pa-
tients with CD and a positive family history were recruited from
the University College London Hospital. We used genome-wide,
single-nucleotide polymorphism data to assess the burden of
common CD-associated risk variants and for linkage analysis.
Exome sequencing was performed and rare variants that were
predicted to be deleterious and were observed at a high fre-
quency in cases were prioritized. We undertook within-family
association analysis after imputation and assessed candidate
variants for evidence of association with CD in an independent
cohort of Ashkenazi Jewish individuals. We examined the ef-
fects of a variant in DUOX2 on hydrogen peroxide production in
HEK293 cells. RESULTS: We identiﬁed 2 families (1 with >800
members and 1 with >200 members) containing 54 and
26 cases of CD or colitis, respectively. Both families had a sig-
niﬁcant enrichment of previously described common
CD-associated risk variants. No genome-wide signiﬁcant linkage
was observed. Exome sequencing identiﬁed candidate variants,
including a missense mutation in DUOX2 that impaired its
function and a frameshift mutation in CSF2RB that was asso-
ciated with CD in an independent cohort of Ashkenazi Jewish
individuals. CONCLUSIONS: In a study of 2 large Ashkenazi
Jewish with multiple cases of CD, we found the genetic basis of
the disease to be complex, with a role for common and rare
genetic variants. We identiﬁed a frameshift mutation in CSF2RB
that was replicated in an independent cohort. These ﬁndings
show the value of family studies and the importance of the
innate immune system in the pathogenesis of CD.
Keywords: Inﬂammatory Bowel Disease; Pedigree; Complex
Disease; Population Isolate.
rohn’s disease (CD) is a chronic, relapsing, and0016-5085/$36.00
http://dx.doi.org/10.1053/j.gastro.2016.06.040Cremitting disease of unknown etiology characterized
by inﬂammation of the gastrointestinal tract thought toresult from an aberrant immune response to commensal
microorganisms in genetically susceptible individuals.1
CD is highly heritable (sibling recurrence risk, 13–362;
monozygotic twin concordance, 30% compared with 4% in
dizygotic twins).3 Genome-wide association studies (GWAS)
including more than 42,000 cases with inﬂammatory bowel
disease (IBD) (CD and ulcerative colitis [UC]) and more than
53,000 controls have identiﬁed more than 200 disease-
associated loci.4,5 These ﬁndings have informed our under-
standing of the pathogenesis of CD; however, the effect sizes
of the variants are small and combined they explain
approximately 14% of the disease heritability.4
The Ashkenazi Jewish (AJ) population is a genetic isolate
estimated to have arisen from 250 to 420 individuals
approximately 25–32 generations ago.6 AJs are enriched for
mutations associated with rare Mendelian7 and common
complex diseases (eg, Parkinson’s disease8), and have an
approximate 4-fold increased prevalence of CD.9 Some
CD-associated loci described in non-Jewish populations also
are associated in AJs and 5 novel AJ CD loci were identiﬁed
by a GWAS.10 These, however, are unable to account for the
increased prevalence of CD in AJs,10 suggesting unidentiﬁed,
potentially rare, AJ-speciﬁc, genetic variants.
The study of large multiply affected families has the
ability to identify rare, more highly penetrant variants.11
However, it has not been used successfully with IBD, in
part because of the small sizes of the families described: of
more than 1000 families recruited by a European-wide
consortium, the largest included 7 cases.12 An AJ family
with 18 cases of IBD was described, although this family
October 2016 Genetics of CD in Ashkenazi Jewish Families 699was dually afﬂicted with basal cell nevus syndrome13 and
genetic analysis did not identify a mutation causing the IBD.
We report the characterization of 2 large families with CD,
from the ultra-Orthodox AJ community, with 54 and 26 cases
of CD. Genetic analyses included examining CD-associated
GWAS variants, linkage analysis, and exome sequencing
with a view to identifying novel causal mutations. This study
shows the genetic complexity of familial CD with a role for
both common and rare variants, including a CSF2RB frame-
shift mutation that replicated in an independent cohort.BA
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Ethical Considerations
Ethical and research governance approval was provided by
the National Research Ethics Service London Surrey Borders
Committee (10/H0806/115) and the University College Lon-
don (UCL) Research Ethics Committee (6054/001). Written
informed consent was provided by all participants.
Recruitment and Phenotyping
AJ CD patients with a positive family history were recruited
from the University College London Hospital and from general
practices within North London. The disease status of affected
individuals (cases) was established with reference to available
clinical information. The absence of disease in unaffected in-
dividuals was not conﬁrmed.
Pedigree Drawing
Pedigrees were drawn using the Graphviz (http://www.
graphviz.org/)14 circo function or the R package (https://
www.r-project.org/) kinship2.15 Pedigrees have been modi-
ﬁed to protect the anonymity of the families while maintaining
the total number and distribution of individuals.
DNA Samples
DNA was obtained from saliva collected using Oragene
OG-500 DNA self-collection kits (Genotek, Ottawa, Ontario,
Canada) or as described by Quinque et al.16 DNA was extracted
by ethanol precipitation or by using QIAamp Mini spin columns
(Qiagen, Hilden, Germany).
Genome-Wide Single-Nucleotide Polymorphism
Genotyping and Quality Control
Single-nucleotide polymorphisms (SNPs) were genotyped on
the Illumina HumanCytoSNPv12 (Illumina, San Diego, CA) (n ¼
135) or the Illumina HumanCoreExome-24 (n ¼ 282) and called
using Illumina BeadStudio. Quality control was undertaken using
PLINK (v1.07, http://pngu.mgh.harvard.edu/wpurcell/plink/),17
removing SNPs with more than 1% missingness, minor allele
frequencies less than 1%, and those with Hardy–Weinberg devi-
ation in founders at a chi-squared P value less than 1  10-5,
leaving 288,413 and532,426 SNPs on theHumanCytoSNPv12 and
HumanExome-24 arrays, respectively, of which 113,429 were
shared. The genotypes of any SNPs showing Mendelian inconsis-
tent inheritancewere set tomissing in the parents and offspring in
which the conﬂict was observed. Familial relationships were
conﬁrmed by pairwise kinship estimates.Ancestry Assessment
The AJ ancestry of all individuals was conﬁrmed using
principal component analysis (see the Supplementary Materials
and Methods section for more detail).
Population Level Genome-Wide Imputation
This was performed using the HumanCytoSNPv12 and
HumanCoreExome-24 data separately. SNPs were phased using
SHAPEIT2 (v2r790, https://mathgen.stats.ox.ac.uk/genetics_
software/shapeit/shapeit.html)18 with duoHMM.19 Imputation
was performed using IMPUTE2 (v2.3.2, https://mathgen.stats.ox.
ac.uk/impute/impute_v2.html)20 with 1000 Genomes phase 3
data as reference. Imputed SNPs with information metric (INFO)
greater than 0.7 were retained and genotypes with a probability
greater than 0.9 were called. Variants homozygous in both parents
and missing in children were populated. Data were ﬁltered with
PLINK, removing SNPswithmore than20%missingness (a relaxed
threshold to minimize data losses given the stringent imputation
thresholds) and individuals with more than 10% missingness.
Genetic Risk Score and Association Analysis
Using Known CD Risk Variants
Imputed genotypes for 124 GWAS CD loci were available (of
144 examined).4,10 The 3 main CD-associated NOD2 variants
(rs2066844/p.R702W, rs2066845/p.G908R, and rs2066847/
p.L1007fsinsC) were genotyped by Sanger sequencing (as per
Lesage et al21) or using the iPLEX Gold Assay (Sequenom, San
Diego, CA). For family-based association analysis, a mixed
model analysis was performed using linkage disequilibrium
adjusted kinships (LDAK, v5.94),22 which extends a standard
linear regression model by including a random effect (with
covariance speciﬁed by the kinship estimated from genome-
wide SNP data) designed to account for correlations owing to
family relatedness. Signiﬁcance was assessed using a Wald test.
Genetic risk scores (GRS) were calculated with Mangrove
(v1.1),23 assuming additivity within and between loci, except
for NOD2. Reference allele frequencies (RAFs) and odds ratios
(ORs) from Jostins et al4 and Kenny et al10 were used; for the
NOD2 variants they were calculated from Zhang et al.24 GRS
were compared with an empiric distribution in 1000 CD cases
and controls simulated using RAFs and ORs. Unaffected family
members were categorized into those with and without at least
1 affected ﬁrst-degree relative (FiDR). Statistical comparisons
were made using the Mann–Whitney–Wilcoxon test.
Linkage Analysis
A linkage disequilibrium–pruned informativemarker setwas
selected for linkage analysis with AJ-speciﬁc RAFs (see the
Supplementary Materials and Methods section). Input ﬁles
were generated using MEGA2 (v4.7.0, https://watson.hgen.pitt.
edu/mega2.html).25 Affected-only parametric linkage analyses
were performed using SwiftLink (https://github.com/ajm/
swiftlink),26 with a 0.5 centiMorgan map and a phenocopy rate
of 5% (see the Supplementary Materials and Methods section).
Haplotype Flow Reconstruction
The reconstruction of haplotype ﬂow was undertaken to
enable the maximum number of cases sharing a founder haplo-
type to be examined and to permit imputation of exome sequence
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which the ﬂow of haplotypes ascertained by Merlin (v1.1.2,
http://csg.sph.umich.edu//abecasis/merlin/index.html)27 was
reassembled across split pedigrees using pairwise identical-by-
descent probabilities (see the Supplementary Materials and
Methods section).Exome Sequencing
Data generation. Exome sequencing was performed on
DNA from all cases available (46 in Family A and 18 in Family
B) and a selection of unaffected family members and AJ con-
trols (n ¼ 72) (see the Supplementary Materials and Methods
section). Target enrichment was performed using the Agilent
SureSelect Human All Exon 50 Mb kit (Agilent, Santa Clara, CA),
the BGI 59 Mb Exome Enrichment kit (BGI, Hong Kong, China),
or the Agilent SureSelect Exome V4 kit. Sequencing was
performed on an Illumina HiSeq 2000 (Illumina), generating
75–100 bp paired-end reads, at the Wellcome Trust
Sanger Institute (Hinxton, UK), BGI, or Macrogen (Seoul, South
Korea).
Data processing. Sequence reads were aligned to Build
37 of the reference genome using Novoalign (v3.02.08) (Novo-
craft, Selangor, Malaysia). Duplicate reads were marked using
Picard (Broad Institute, Cambridge, MA, https://broadinstitute.
github.io/picard/) tools. As per GATK28 (v3.5, Broad Institute,
Cambridge, MA, https://software.broadinstitute.org/gatk/) Best
Practices,29,30 initial genotypes were called using Hap-
lotypeCaller and joint calling was performed using Genoty-
peGVCFs, with more than 4200 samples comprising UCL Exome
Sequence Consortium, a local collection of exomes from a variety
of cohorts. Single-nucleotide variantswereﬁltered using variant-
quality recalibration scores. Variants with genotype quality less
than 10 or depth less than 5 were excluded. HumanCoreExome-
24 genotypes were incorporated where available.
Within-family imputation. Genotypes of family mem-
bers from whom genome-wide SNP data but no exome
sequence data were available (5 affected and 180 unaffected in
Family A and 76 unaffected in Family B) were imputed using
the reconstructed haplotype ﬂow data (see the Supplementary
Materials and Methods section). This yielded data for a
maximum of 254 and 114 individuals in Families A and B,
respectively.
Variant annotation, ﬁltering, and prior-
itization. Variants were annotated using Ensembl Variant
Effect Predictor (VEP) (v82, http://www.ensembl.org/info/
docs/tools/vep/index.html),31 retaining start, stop, splice,
frameshift, or stop mutations, or missense mutations predicted
to be deleterious by either CAROL32 or Condel33 (in any tran-
script), or with a CADD34 score greater than 20. Variants at a
frequency greater than 2.5% in any 1000 Genomes35 or ExAC36
populations or greater than 5% in 1745 unrelated individuals
from UCLex or 1967 non-IBD AJs (Broad Institute AJ Crohn’s
disease and control exome replication data set [AJex], see later)
were excluded. Finally, variants were excluded if they were
missing in more than 20 cases in Family A or in more than 10
cases in Family B. Variants observed in 60% or more of the
cases within each family or the 3 main subfamilies of Family A
(A0, A1, and A2) were prioritized. The analysis was restricted
to the autosomes.
Association testing and signiﬁcance asses-
sment. For each variant, within-family, kinship-adjustedassociation testing was performed using LDAK,22 with a Wald
test for signiﬁcance assessment. Variants were ranked by
minimum P value within each subfamily or family.
Replication Cohort: AJex
The RAFs of candidate variants and independent evidence
of association to CD was assessed in a cohort of 1855 CD cases
and 3044 controls of genetically conﬁrmed AJ ancestry exome
sequenced by an international collaborative effort coordinated
by the Broad Institute as part of the Helmsley IBD Exomes
Program.
Candidate Variant Genotyping
The DUOX2 and CSF2RB variants were genotyped by Sanger
sequencing (see the Supplementary Materials and Methods
section).
DUOX2 Functional Experiments
The functional consequences of DUOX2 P303R were
assessed in vitro using HEK293 cells co-transfected with vec-
tors encoding wild-type or mutant DUOX2 and DUOXA2
(required heterodimerization partner) as described by Gras-
berger and Refetoff.37 DUOX2 reduced nicotinamide adenine
dinucleotide phosphate oxidase activity was stimulated by
ionomycin and 12-O-tetradecanoylphorbol-13-acetate as
described by Rigutto et al,38 and hydrogen peroxide production
was measured using AmplexRed horseradish peroxidase. Sur-
face and total expression of N-terminal epitope tagged wild-
type and P303R DUOX2 were determined by ﬂow cytometry
of nonpermeabilized and saponin-permeabilized cells as
described by Grasberger et al.39 Further details are provided in
the Supplementary Materials and Methods section. Repeated
independent transfections were performed for each assay.
Statistical analyses were performed using the Student t test for
single comparisons and using analysis of variance with Sidak
correction test for multiple comparisons.
Results
Description of the Families and Phenotype
Family A comprised a total of approximately 750 in-
dividuals across the ﬁrst 4 generations including 48 cases
(prevalence, 6.4%) (Figure 1A). There were an additional 6
cases in the ﬁfth generation, totaling 54 (Figure 2A). The
cases were distributed predominantly within 3 subfamilies:
A0 (n ¼ 10), A1 (n ¼ 19), and A2 (n ¼ 17), with prevalences
of 6.9%, 15.8%, and 13.3%, respectively. The remaining
cases were distributed in subfamilies A3 (n ¼ 4), A4 (n ¼ 2),
and A5 (n ¼ 2), with prevalences of 3.0%, 2.9%, and 1.6%,
respectively (a statistically signiﬁcantly lower rate, P < 8 
10-6). Each sibship comprised an average of 10 children
(quartiles, 8–11).
Individuals in Family A lived in at least 8 cities in 4
countries. There was no evidence of a bias for maternal
transmission, or a sex bias (25 males, 29 females; P ¼ .68).
For the majority of cases (n ¼ 48), diagnoses were
conﬁrmed by the patient’s physician or by review of their
medical records. For the remaining cases, diagnoses were
supported by the clinical, investigative, and treatment
Figure 1. Pedigrees showing all affected (ﬁlled symbols,
larger for clarity) and unaffected individuals in the ﬁrst 4
generations of (A) Family A and (B) Family B. All individuals
are shown as circles regardless of sex. (A) Subfamilies have
been labeled A0–A6. The pedigrees have been modiﬁed
slightly for reasons of anonymity. Deceased individuals have
been included but not identiﬁed. For simplicity, founders
entering the pedigrees have not been included.
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colitis, or indeterminate colitis; because CD commonly is
misdiagnosed as UC40,41 and the overwhelming manifesta-
tion was that of CD, we have labeled the disease in this
family as such. None of the affected individuals were ciga-
rette smokers. The location of disease in the bowel was
variable, with the majority (n ¼ 38) having ileal or ileoco-
lonic disease. The disease behavior included stricturing
and/or ﬁstulation in 18 cases and 14 had undergone sur-
gical resections. The median age at onset was 18 years
(quartiles, 13–21), and the minimum was 8 years. A total of
27.5% of the unaffected individuals were age 20 or younger,
and a proportion of these patients are likely to develop the
disease in the future.Family B comprised approximately 180 individuals
across the ﬁrst 4 generations including 18 cases, with a
prevalence of 9.9% (Figure 1B). In total, there were 23 cases
within 2 subfamilies with prevalence rates of 9.8% and
10.0% (Figure 2B), and 3 more distantly related cases that
were not included. Each sibship comprised an average of 8
children (quartiles, 6–10).
Individuals in Family B lived in at least 4 cities in 3
countries. There was a slight predominance of affected
males, although this was not statistically signiﬁcant (16
males, 7 females; P ¼ .09). Of the 19 currently living affected
individuals within the 2 main subfamilies from whom DNA
was obtained, diagnoses were conﬁrmed by the patient’s
physician or by review of their medical records for all but
one. One patient had severe colonic disease with nonspeciﬁc
endoscopic and histopathologic features; all others had a
diagnosis of CD. Five of the affected members of this family
were cigarette smokers. The median age at onset was 23
years (quartiles, 16–27). A total of 8.2% of the unaffected
individuals were age 20 or younger. Similar to Family A, the
majority of patients had ileocolonic disease. The disease
behavior included stricturing and/or ﬁstulation in 9 cases,
and 10 had undergone surgical resections.
In both families, the cases had been described as idio-
pathic CD (or colitis) and there were no consistently
observed extraintestinal manifestations. Principal compo-
nent analysis conﬁrmed all individuals examined to be of
AJ ancestry (Supplementary Figure 1). The relatedness was
observed to match that expected based on the pedigree
structures and there was no evidence of inbreeding.
Although the pattern of disease segregation did not
conform to that of a Mendelian trait, there was clear evi-
dence of familial aggregation: in Family A, 41 of 54 cases
(39 of 46 in subfamilies A0, A1, and A2) had at least 1
affected FiDR. In Family B, all but 1 of the cases had at least
1 affected FiDR.
Given the size of the families, with a population preva-
lence of 1.3% (a 4-fold increase of the European CD prev-
alence42) and assuming independence of disease risk using
a binomial model, one would expect to observe 11 (upper
95% conﬁdence interval, 16) and 3 (upper 95% conﬁdence
interval, 6) cases in the ﬁrst 4 generations of Families A and
B, respectively, compared with the 48 and 18 observed,
respectively.The Role of Known CD-Associated Variants
Data were available for 127 CD-associated variants in
293 and 110 individuals in Families A and B, respectively.
Association analysis, correcting for relatedness using LDAK,
showed that 10 and 15 of these variants were nominally
signiﬁcant (P < .05) in Families A and B, respectively
(Supplementary Table 1). The NOD2 frameshift variant
(rs2066847) was the most signiﬁcantly associated with
disease in Family A (P ¼ 7  10-4), and the ﬁfth most sig-
niﬁcant in Family B (P ¼ .003).
In Family B, only 4 of 19 cases were wild type for all 3
NOD2 variants examined (Figure 2B). However, in Family A,
a large number of the cases (26 of 51) were wild type,
Figure 2. Pedigrees showing all affected individuals (ﬁlled symbols) and their connecting relatives in (A) Family A and (B) Family
B. All individuals are been shown as diamonds regardless of sex. (A) Subfamilies have been labeled A0–A5. The genotypes of a
frameshift mutation in CSF2RB p.S709LX22 in A, a missense variant in DUOX2 p.P303R in B (0 wild type, X heterozygous) and
a composite of the 3 NOD2 variants examined (p.G908R, p.R702W, p.L1007fsinsC) (0, wild type; 1, heterozygous; or 2, ho-
mozygous or compound heterozygous) are shown where available.
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of 18) (Figure 2A). Consistent with the low penetrance of
NOD2 variants, 12 unaffected individuals in Family A and 2
in Family B were either compound heterozygous or
homozygous.
The cases in Family A harbored a signiﬁcant burden of
common CD-associated variants with an approximately
2.9-fold higher median GRS than the simulated CD popula-
tion (Figure 3A). Cases had a higher GRS than unaffected
individuals with (P ¼ .038, without correction for 5
comparisons) and without (P ¼ 7.4  10-7) an affected
FiDR. Unaffected individuals with at least 1 affected FiDR
had a signiﬁcantly greater GRS than those without
(P ¼ 1.2  10-4). The median GRS of spouse controls
(founders with no affected descendants) approximated to
that of the theoretical control population. In Family B
(Figure 3B), there was no signiﬁcant difference in GRS
between cases and unaffected individuals with at least 1
affected FiDR; however, unaffected individuals with an
affected FiDR did have a higher GRS than those without
(P ¼ .009). Although the prevalence of disease was
much greater in subfamilies A1 and A2 compared
with A3, A4, and A5, the GRS (in both affected and unaf-
fected individuals) was not increased proportionately
(Supplementary Figure 2).Linkage Analysis
Parametric analyses failed to identify 1 or more loci
signiﬁcantly segregating with disease. The maximum loga-
rithm of the odds (base 10) scores for Family A; Family A
subfamilies A0, A1, and A2 together; and Family B were all
less than 1.2. A variety of strategies were used, varying the
deﬁnition of the affected status (eg, only those with histo-
logically conﬁrmed CD) and altering the phenocopy rate.
Maximal haplotype sharing conﬁrmed these results and
showed that, at most, 26 of 50 affected individuals within
Family A and 14 of 17 within Family B shared a locus
identical by descent. At the NOD2 locus, at most, 10 of 17
affected individuals were identical by descent in Family B.Exome Variants
A total of 68,881 exonic variants were seen in at least 1
affected individual in Family A and 52,682 exonic variants in
Family B (an average of 18,221 per individual across both
families). After ﬁltering, 66 variants were prioritized in
Family A and 11 in Family B (Supplementary Tables 2 and 3,
respectively). No variants known to cause monogenic in-
testinal inﬂammation43 were observed. For both families,
the minimum theoretical LDAK P value for a variant segre-
gating to all affected individuals and no terminal unaffected
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Figure 3.GRS in affected and unaffected individuals in (A)
Family A and (B) Family B. Unaffected individuals have been
divided into those with (þaFiDR) and without (-aFiDR) at least
1 affected ﬁrst-degree relative. Spouse controls; founders
with no affected descendants; spouse parents; founders with
1 or more affected offspring. (A and B) The distribution of
GRS in a simulated theoretical control and Crohn’s disease
population (along with the corresponding medians) is
indicated. *P <.05, **P <.01, and ***P <.001 (Man-
n–Whitney–Wilcoxon test).
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pedigree variant imputation was successful for 62 of 66
and 9 of 11 of the prioritized variants in Families A and B,
respectively.
In Family A, 20 of the prioritized variants were enriched
in affected compared with unaffected family members at a
LDAK P value less than .05 within either the entire family or
1 of the 3 main subfamilies (Supplementary Table 2). The
top 10 variants ranked by minimum P value across the
family or in any subfamily are shown in Table 1. Similar
exome ﬁndings were observed when the cases labeled as UC
or indeterminate colitis were excluded. For 16 of these
variants, data were available from AJex; 2 variants were
nominally signiﬁcantly (P < .05) associated with AJ CD: the
NOD2 frameshift rs2066847 (AJex P ¼ 2.1  10-25) and a
frameshift mutation in CSF2RB (p.S709LX22). The latter was
704 Levine et al Gastroenterology Vol. 151, No. 4
BASIC
AND
TRANSLATIONAL
ATobserved in 18 of 40 affected and 27 of 103 unaffected in-
dividuals in the family, with a particular enrichment in
subfamily A0 (8 of 9 affected and 7 of 24 unaffected; LDAK
P ¼ 6.1  10-5). This variant was associated with CD in AJex
at a P value of .0091. The identical CSF2RB frameshift
mutation was identiﬁed in a concurrently published study of
2992 unrelated CD cases and 9594 controls, all of AJ
ancestry, in which it was associated with disease at a P value
of 3.42  10-6, with an OR of 1.5.44 The composition of the
case and control cohorts studied by Chuang et al44 partially
overlaps with AJex; however, the discovery of this variant in
Family A and by Chuang et al44 were independent.
In Family B, 7 of the 11 prioritized variants showed
enrichment in affected compared with unaffected family
members at a LDAK P value less than .05 (Table 2). A
missense variant in the DUOX2 gene (p.P303R) was shared
by the largest number of affected individuals (15 of 19) and
yielded the most signiﬁcant P value (LDAK P ¼ 1.6  10-4).
The second most commonly shared variant was the NOD2
frameshift (LDAK P ¼ 9.7  10-3). For all of the 7 variants
achieving a P value less than .05 within the family, data
were available from AJex; the NOD2 frameshift and a variant
in the gene PLA2G4E were associated at a P value less than
.05 in these data; however, the direction of effect of the
latter was opposite that seen in Family B. Considering all 3
NOD2 variants, 12 of 19 affected individuals were hetero-
zygous for the DUOX2 variant and had at least 1 NOD2
variant as compared with only 12 of 88 unaffected in-
dividuals. A missense variant in RNF186 (rs41264113,
p.A64T) recently associated with UC45 was observed in 12
of 19 cases, although it was not enriched in cases (P ¼ .39).
There was no difference in the clinical phenotype of
cases harboring the CSF2RB or DUOX2 variants relative to
the noncarrier affected individuals within the families.
Functional Assessment of the DUOX2 Variant
In DUOXA2-reconstituted HEK293 cells, hydrogen
peroxide production by DUOX2 P303R was reduced signif-
icantly compared with the wild-type protein at a range of
vector concentrations (Figure 4A). Similar ﬁndings were
observed in HeLa cells (data not shown). Neither wild-type
nor DUOX2 P303R resulted in signiﬁcant superoxide pro-
duction, indicating that lack of hydrogen peroxide produc-
tion by DUOX2 P303R was not owing to deﬁcientTable 2.The Seven Prioritized Exome Variants in Family B
Chromosome Position Ref Alt Gene
15 45402883 G C DUOX2
15 42281657 C T PLA2G4E 8.0
5 44809369 C T MRPS30
16 50763778 G GC NOD2
1 179660076 T TGAGG TDRD5
3 48414274 C T FBXW12
1 117492067 T G PTGFRN 1.9
A, allele frequency in cases; AJexOR, replication odds ratio; AJe
allele frequency; P, LDAK P value; ND, no data available; Ref, rintramolecular dismutation of superoxide (Supplementary
Figure 3). Flow cytometric analysis of N-terminal epitope-
tagged DUOX2 showed that the reduced activity of P303R
could be accounted for by a failure to efﬁciently trafﬁc the
variant protein to the cell surface despite normal intracel-
lular expression level (Figure 4C–E and Supplementary
Figure 4). Simulation of heterozygous conditions by
co-expression of DUOX2 P303R with the wild-type protein
showed partial interference of the variant protein with the
surface expression and function of wild-type DUOX2
(Figure 4B and F). Based on these in vitro ﬁndings, the
severity of DUOX2 loss in heterozygous carriers is predicted
to be equivalent to a monoallelic deletion mutation.Discussion
This study identiﬁed 2 large families with CD. However,
even in such large families and despite a plethora of genetic
data, disentangling the causes of the disease proved
challenging.
In both families there was a considerable burden of GWAS
CD-associated risk variants in both the affected and unaffected
individuals. In Family A therewas amarginal increase in GRS in
affected individuals compared with unaffected individuals,
with at least 1 affected FiDR; however, no such difference was
observed in Family B. Furthermore, in Family A the GRS did not
correlate with prevalence by subfamily, suggesting the pres-
ence of additional etiologic factors in those subfamilies with a
higher prevalence. In the absence of AJ-speciﬁc RAFs and ORs
for all risk variants and an accurate AJ population disease
prevalence, the role of common variation in the familial ag-
gregation cannot be quantitated with precision; however, it is
likely to contribute signiﬁcantly.
Linkage analysis is hampered by the presence of pheno-
copies (cases with a different genetic cause for their disease),
which in these families are probable given the high preva-
lence of CD in the AJ population and the family sizes. The
absence of linkage does not, however, exclude the possibility
that a large subset of the cases within each family (or sub-
family) might share a rare damaging variant, as exempliﬁed
by theNOD2 frameshift, whichwas prioritized successfully by
exome sequencing. However, no exome variant (including the
NOD2 frameshift) met the minimum theoretical P value or
achieved genome-wide signiﬁcance (P < 5  10-8).46ExAC A U P AJexOR AJexP
0.011 0.37 0.15 1.6  10-4 1.2 .26
 10-4 0.32 0.12 3.2  10-4 0.6 .032
0.011 0.29 0.15 8.2  10-3 1.1 .84
0.013 0.42 0.21 9.7  10-3 3.1 2.1  10-25
ND 0.29 0.15 .019 0.7 .25
0.014 0.32 0.14 .020 1.1 .50
 10-4 0.29 0.14 .030 1.3 .51
xP, replication P value; Alt, alternative allele; ExAC, population
eference allele; U, allele frequency in unaffected individuals.
Figure 4. Functional characterization of the effect of DUOX2 P303R in vitro. (A) Hydrogen peroxide production from DUOXA2-
reconstituted HEK293 cells transfected with 303P (wild type) and 303R DUOX2 at a range of vector concentrations. Data
represent means ± SD of 3 (basal) and 6 (stimulated) independent experiments. The total amount of DNA per transfection was
kept constant by adjusting with empty vector. ****P < .0001 (Student t test). (B) To simulate heterozygosity, cells were co-
transfected with the indicated combinations of empty vector (null), DUOX2 303P, or 303R plasmids. Values represent
means ± SD from 6 experiments per transfection dose. The activity of P/R (heterozygous 303P/303R) is signiﬁcantly lower than
P/P (homozygous 303P), but indistinguishable from P/null (monoallelic deletion 303P/null), P/R vs P/P: **P < .01 (analysis of
variance with Sidak correction). (C) Topology model of the DUOX2/DUOXA2 complex at the plasma membrane showing the
location of the introduced hemagglutinin (HA) epitope tag (DUOX2) and green ﬂuorescent protein (GFP) fusion (DUOXA2). (D)
Representative ﬂow cytometry scatterplots and histograms showing the detection of the HA epitope and GFP ﬂuorescence in
cells transfected with the indicated plasmids. (E) Summary of DUOX2 and DUOXA2 expression assessed by ﬂow cytometry.
For each experiment (open circles), data are expressed relative to the value for the 303P/DUOXA2 transfection (set to 100).
a.u., arbitrary units; ****P < .0001; ns, P > .05 (Student t test). (F) To assess the surface expression of 303P and 303R DUOX2
under heterozygous conditions, the expression of the HA epitope at the cell surface was determined in cells co-transfected
with equal amounts of 2 DUOX2 plasmids, with only 1 plasmid containing an HA tag. Values represent means ± SD from 3
experiments per transfection dose. Results suggest interference of 303R with surface expression of 303P: HA-P/R vs HA-P/P:
*P < .05 (analysis of variance with Sidak correction).
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may be overcome by using independent replication co-
horts. This, however, requires large sample sizes in thecase of rare variants.46 Nonetheless, nominal signiﬁcance
was obtained for 2 variants, the NOD2 and CSF2RB
frameshifts, the latter at a P value of .009. Theoretically, it
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threshold of P less than .0025 (20 variants tested).
However, importantly, a concurrently published study
independently discovered the identical CSF2RB frameshift
mutation in the context of AJ CD and provided strong
statistical evidence for the association. Furthermore,
functional investigations have shown that this variant
impairs STAT5 phosphorylation after granulocyte-
macrophage colony-stimulating factor (GM-CSF)
stimulation both in transfected HEK293 cells and in
monocyte-derived macrophages isolated from carriers.44
Homozygous loss-of-function mutations in CSF2RB have
been described in pulmonary alveolar proteinosis, in which
there is completely absent GM-CSF–induced STAT5 phos-
phorylation.47,48 None of the patients in our study with the
CSF2RB frameshift showed a pulmonary phenotype, pre-
sumably because of the existence of some residual CSF2RB
activity.
CSF2RB is an excellent candidate for causal involvement
in the pathogenesis of CD: the protein forms the b chain of
the interleukin (IL)3, IL5, and GM-CSF receptors, which
signal through STAT5 to inﬂuence the differentiation, pro-
liferation, and function of hematopoietic cells. Loss of GM-
CSF signaling is associated with compromised immunity.49
This is pertinent in the context of CD as an immunodeﬁ-
ciency disease in which the innate immune system fails to
adequately clear microorganisms that have breached the
mucosal barrier, owing to impaired cytokine secretion
causing defective neutrophil recruitment, with a resulting
secondary inﬂammatory reaction.50–53
Although not signiﬁcant in AJex despite sufﬁcient power
given its RAF (assuming a modestly large effect size), the
missense variant in DUOX2 in Family B was of interest given
the established role of DUOX2 in CD. DUOX2 is amember of the
large reduced nicotinamide adenine dinucleotide phosphate
oxidase family of enzymes that are defective in chronic gran-
ulomatous disease.43 Knockdown of the DUOX2 homologue in
invertebrates and mice results in an impaired tolerance to
enteric bacteria.54 DUOX2 is overexpressed in intestinal biopsy
specimens from CD patients associated with alterations in the
intestinalmicrobiome.55 Two very rare functionalmutations in
DUOX2 were recently identiﬁed in 2 patients with very early
onset IBD in a candidate gene study.56 Of relevance given the
overlap in caseswith bothNOD2 andDUOX2 variants in Family
B, these 2 proteins have been shown to interact (mediated via
the leucine-rich repeat domain of NOD2 in which
CD-associated variants cluster) to protect cells from bacterial
invasion.57 Genetic variation affecting the function of these
proteins could alter CD risk through disrupting their interac-
tion or by independently modulating their actions in host de-
fense. Given the low frequency of the DUOX2 and NOD2
variants, replicating this association would require very large
sample sizes. The observedDUOX2 variant (P303R) impairs its
function; however, even with functional data in the absence of
statistical replication of the association of the variant to CD, we
cannot infer causality.58
On the basis of existing functional data, a number of other
prioritized candidate variants are worthy of note. NLRP2 is a
NOD-like receptor and a component of the inﬂammasome;reducing endogenous levels of the protein has been shown to
reduce lipopolysaccharide-induced secretion of IL1b in
monocytes,59 which is of relevance given the defective
proinﬂammatory cytokine secretion observed from CD mac-
rophages.51,60 ZC3H18 is involved in IkB kinase and nuclear
factor-kB activation,61 a pathway of established importance in
CD, and MEGF10 is a phagocytic receptor involved in
apoptosis.62 However, as per the DUOX2 variant, robust sta-
tistical evidence of disease association remains of overarching
importance.58
We have assumed that each variant acts independently.
However, it is possible that a selection of the prioritized
candidate variants identiﬁed act in consort. For example, on
a background of NOD2 variants impairing immune cell
activation,63 a DUOX2 variant altering mucosal immune
homeostasis could cause CD. The problem with this model,
as is the case for epistatic interactions of common variants
underlying truly polygenic traits,64 is the difﬁculty in
achieving statistical power to detect an association resulting
from the requirement for the carriage of multiple rare var-
iants. Furthermore, it is possible that novel risk variants
preferentially affect those individuals with a low GRS23 and
that this could be used for variant prioritization.
Familial aggregation does not necessarily imply an un-
derlying genetic etiology. Familial clustering of IBD has been
proposed to be environmental.65 However, in the families
under study a primary environmental etiologic explanation is
unlikely. If the disease was caused by an environmental
factor, one would expect it to manifest equally frequently in
all those living within the same household. However, across
all nuclear families from Families A and B with cases, there
was only 1 occurrence of a dually affected couple. In addi-
tion, the cases were distributed across multiple cousinships
within different cities worldwide; it is difﬁcult to envisage
the propagation (or coincidental occurrence) of an environ-
mental risk factor across these distances. Finally, the highly
variable familial burden of disease observed in this popula-
tion in the context of its environmental homogeneity argues
in favor of a genetic etiology. It is possible, however, that an
environmental factor (or factors) contribute to a reduced
penetrance, for example, a genetically susceptible individual
may develop the disease only after an environmental insult
(eg, acute gastroenteritis66) that could occur stochastically.
This study has shown the complexity of the genetics of
CD in 2 large AJ families with multiple cases of the disease.
The role of common CD-associated variants has been high-
lighted and a monogenic etiology has been excluded. A
number of candidate variants have been prioritized, most
notably a novel frameshift mutation in the gene CSF2RB for
which independent replication evidence has been obtained.
The identiﬁcation of this mutation and its independent
discovery by Chuang et al44 consolidates the causal role of
this mutation in CD and validates the approach of using
exome sequencing in large families. Further candidate var-
iants identiﬁed in this study may be implicated in CD;
showing this will rely on further genetic and functional in-
vestigations. Regarding our understanding of CD pathogen-
esis, the identiﬁcation of a mutation in CSF2RB, a protein
common to multiple cytokine receptors, reinforces the
October 2016 Genetics of CD in Ashkenazi Jewish Families 707importance of the innate immune system as a ﬁrst defense
against penetration of the microbiome through the intestinal
mucosa.52Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/j.
gastro.2016.06.040.ReferencesBA
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